N. Romero

Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy

Johannes C. Hermann, C. Lukacs, Seng-Lai Tan, 2013, Arthritis Research & Therapy.